12th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160082059 | METHOD FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES - Provided herein is a method for preventing or treating neurodegenerative disease in a subject, comprising administrating to the subject an effective amount of a composition which comprises a semen biotae extract. The neurodegenerative disease is associated with α-synuclein, such as Alzheimer's disease, Parkinson's disease, Huntington disease, or Amyotrophic lateral sclerosis. | 2016-03-24 |
20160082060 | MILK YIELD AND/OR MILK QUALITY IMPROVING AGENT, PERINATAL DISEASE PREVENTIVE OR THERAPEUTIC AGENT, AND REPRODUCTIVITY IMPROVING AGENT FOR RUMINANT - An object of the present invention is to improve the milk yield and/or milk quality of a ruminant for milk production, to prevent or treat a perinatal disease of a ruminant, and to improve the reproductivity of ruminant. In order to solve the above-mentioned problem, the following is provided. An agent for improving at least one of milk yield and milk quality of a ruminant, comprising at least one of cashew nut shell liquid, heat-treated cashew nut shell liquid, anacardic acid, cardanol, and cardol. An agent for preventing or treating a perinatal disease of a ruminant, comprising at least one of cashew nut shell liquid, heat-treated cashew nut shell liquid, anacardic acid, cardanol, and cardol. An agent for improving reproductivity of a ruminant, comprising at least one of cashew nut shell liquid, heat-treated cashew nut shell liquid, anacardic acid, cardanol, and cardol. | 2016-03-24 |
20160082061 | NUTRITIONAL COMPOSITION AND METHOD OF MANUFACTURE - A nutritional composition, and method of making it, that includes a carbohydrate, an insulin potentiator, an amino acid, a muscle growth stimulator, an energy increaser, at least one natural supplement for weight loss, reduction of cholesterol levels, and/or increased resistance to stress, and at least one flavoring ingredient. The composition may be provided in dry form for addition to a fluid or in liquid forms. The composition is ingested to improve endurance and muscle tissue repair after exercise. In an embodiment the composition includes vanadyl sulfate, gamma oryzanol, American ginseng, sucralose, and rhodiola rosea. In another embodiment the composition includes vanadyl sulfate, gamma oryzanol, stevia, garcinia cambogia, and diarginine malate. | 2016-03-24 |
20160082062 | THERMO-MODIFIED NUTSHELLS AND METHODS OF TREATING DIARRHEA, ADSORBING TOXINS, PROMOTING GROWTH AND IMPROVING THE OVERALL HEALTH - Compositions comprising thermo-modified nutshells, for example hazelnut shells, are described herein. The compositions can also comprise one or more feed additives, pharmaceutically acceptable diluents and/or excipients. Also included are methods for producing the thermo-modified nutshell compositions, and methods for using the compositions to treat diarrhea and adsorb toxins as well as promote growth and improve the overall health in humans and other animals. | 2016-03-24 |
20160082063 | COMPOSITION FOR PREVENTING OR TREATING STROKE OR DEGENERATIVE BRAIN DISEASE - The present invention relates to a composition for preventing and/or treating a stroke or a degenerative brain disease comprising: at least two substances selected from the group consisting of egg yolk lecithin, glycerol, sodium oleate, medium chain triglyceride and refined fish oil; olive oil; and soybean oil. The composition of the present invention has an excellent neuroprotective effect but no toxicity or side effects, and thus can be effectively and safely used for preventing, treating or ameliorating a stroke or a degenerative brain disease. | 2016-03-24 |
20160082064 | METHOD FOR REGULATING BLOOD GLUCOSE LEVEL - A method for increasing the expression of SIRT1 mRNA and/or decreasing the expression of SOCS3 mRNA, and especially for regulating blood glucose levels in a subject in need thereof is provided. The method comprises administering to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), and combinations thereof: | 2016-03-24 |
20160082065 | PROPHYLACTIC USE OF NEUROPROTECTANTS IN SPORTS-RELATED TRAUMATIC BRAIN INJURY - Dietary supplements for reducing damage to brain cells characterized by loss of brain cells or loss of brain cell function in patients that have suffered from traumatic brain injury (“TBI”) while participating in sports and/or other athletic events are disclosed herein. The Nutraceutical compositions offer possible ameliorating effects for the secondary phase of TBI. Creatine, vitamin E, zinc, magnesium, DHA, and lipoic acid, taken together, offer a prophylactic measure to ameliorate brain damage that occurs during the secondary phase of SRTBI. | 2016-03-24 |
20160082066 | Method Use of Polymethoxyflavones (PMFs) in Body Composition Management - Synergistic composition of | 2016-03-24 |
20160082068 | Topical Transdermal Method for Delivering Nutrients Through the Skin for Expeditied Wound Healing and Skin Rejuvenation - The present invention relates to liquid application for skin rejuvenation created from specific amino acids, lipids, nucleic acids and vitamins. This collection of molecules delivers precisely the factors necessary to a specific site requiring healing; a direct intervention system to most expeditiously remodel skin with building blocks. This delivery is a transdermal topical delivery and healing is via specific molecules that engender a false autocoid reaction rapidly followed by an incremental healing-anti-inflammatory response augmented by very specific GRAS ingredients in the invention and also recruited from the body to this needy site. Energy is brought to site by transdermally delivered protons and enhanced by the local vascular flow initiated by transdermal molecules. | 2016-03-24 |
20160082069 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides pharmaceutical compositions comprising a compound of formula | 2016-03-24 |
20160082070 | METHODS OF TREATMENT USING WATER-SOLUBLE TRYPTOPHAN-CONTAINING PEPTIDES OBTAINED BY THE HYDROLYSIS OF HENS EGGS LYSOZYME - The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45. | 2016-03-24 |
20160082071 | METHODS OF TREATING MYELOID LEUKEMIA - There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent. | 2016-03-24 |
20160082072 | BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS FOR TREATING DRY EYE - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 2016-03-24 |
20160082073 | NOVEL USE - The present invention relates to a combination comprising at least one compound selected from the group consisting of an α-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator, a vitamin, or a pharmaceutically acceptable derivative thereof; and an antimicrobial compound. | 2016-03-24 |
20160082074 | COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION - The invention relates to the use of non-immunosuppressive cyclophilin inhibitors in the treatment of Coronavirus infection in a patient. | 2016-03-24 |
20160082075 | Combination Therapy for Subcutaneous Administration of Glycopeptide Antibiotics - A combination drug therapy is disclosed for the treatment of a patient, such as a human, with a glycopeptide antibiotic. The methods can include subcutaneous administration to a patient of a therapeutically effective amount of a glycopeptide antibiotic, for example, vancomycin, and a compound belonging to the cromones class of anti-inflammatory agents such as cromolyn sodium. The present teachings also provide a therapeutic combination and a kit including the therapeutic combination. | 2016-03-24 |
20160082076 | BRIDGE-HELIX CAP: TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance. | 2016-03-24 |
20160082077 | FLAGELLIN RELATED POLYPEPTIDES AND USES THEREOF - The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described. | 2016-03-24 |
20160082078 | LIQUID CONCENTRATED FORMULA - The invention pertains to a liquid complete nutritional composition suitable for feeding cachectic patients, having an energy density of at least 1.45 kcal/ml. The composition comprises a protein fraction in an amount of 7.8-12 g per 100 ml, a carbohydrate fraction, and a lipid fraction. At least 70 wt. % of the protein fraction can be obtained by demineralising milk, e.g. by ultrafiltration. The carbohydrate fraction (17-27 g per 100 ml) can comprise 0-35 wt. % of sucrose, 15-45 wt. % of other non-reducing mono-, di- and/or trisaccharides, especially trehalose, 5-50 wt. % of other mono- and disaccharides and 5-40 wt. % of tri- and higher saccharides. The product is suitably packaged in small volumes (10-150 ml). | 2016-03-24 |
20160082079 | Wnt Antagonist and Methods of Treatment and Screening - The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use. | 2016-03-24 |
20160082080 | HUMANIN, ANALOGS AND CANCER TREATMENT METHODS AND USES THEREOF - Described herein are methods of enhancing chemotherapeutic treatment of a hyperproliferative disorder by, in part, administering a composition comprising one or more humanin polypeptides to a subject receiving chemotherapy. | 2016-03-24 |
20160082081 | METHODS AND COMPOSITIONS FOR TREATING TRINUCLEOTIDE REPEAT DISORDERS - Disclosed herein are methods and compositions for treating trinucleotide repeat disorders. | 2016-03-24 |
20160082082 | USE OF THERAPEUTIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCER - MUC1 (DF3, CD227, episialin, PEM) is a heavily O-glycosylated heterodimeric protein of >300 kDa, normally expressed abundantly on the apical surface of glandular epithelia. MUC1 mimetic peptides are selectively retained in mammary gland tumors, colon and skin after systemic administration. Moreover, MUC1 mimetic peptides reduce tumor initiation. In addition, MUC1 mimetic peptides can be used in conjunction with other anti-EGFR treatments in the adjuvant context, i.e., after surgery. | 2016-03-24 |
20160082083 | METHOD OF INHIBITING ANGIOGENESIS, TUMORIGENESIS AND CATHEPSIN ACTIVITY - Insulin-like growth factor binding proteins (IGFBPs) and variants thereof, including IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-8 and the C-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin B activity. | 2016-03-24 |
20160082084 | HEART FAILURE TREATMENT - The present invention relates to treating and/or preventing heart failure or one or more individual heart failure phenotypes in mammals using placental growth factor 2 (PlGF-2). | 2016-03-24 |
20160082085 | Co-Administration of a Parvovirus and a Cytokine for Therapy of Pancreatic Cancer - The present invention relates to a combination of a parvovirus and a cytokine, preferably IFN | 2016-03-24 |
20160082086 | SUBMICRON PARTICLES FOR THE TREATMENT OF RADIATION DAMAGE IN PATIENTS - A method of treating a patient exposed to radiation before the patient is thrombocytopenic, comprising: intravenous infusion of protein spheres at a concentration of the protein spheres sufficient to reduce the morbidity and mortality of the irradiated patient. The protein spheres are formed from soluble proteins without the addition of surfactants or detergents, and the protein spheres spontaneously and directly bind at least one coagulation factor without the aid of other molecules which specifically bind the at least one coagulation factor. | 2016-03-24 |
20160082087 | WHITENING PROMOTING AGENT OR ATOPIC DERMATITIS AMELIORATING AGENT - A peptide selected from the group consisting of Hyp-Gly, Pro-Ala-Gly, Gly-Pro, Glu-Hyp-Gly, (Pro-Hyp-Gly) | 2016-03-24 |
20160082088 | COLLAGEN POWDER - Methods are disclosed for preparing a collagen powder, for example which may be used for the preparation of a satiety inducing food product. The collagen powder is suitable as a food additive in food products for the reduction of hunger and as a possible treatment of obesity and its pathophysiological consequenceos, such as metabolic syndrome. | 2016-03-24 |
20160082089 | COMPOSITION FOR TREATING AND PREVENTING ISCHEMIC DAMAGE - The present disclosure relates to a composition for treating and preventing an ischemic injury. More particularly, it relates to a composition containing a peptide derived from a telomerase, which is effective in treating and preventing an ischemic injury. The peptide according to the present disclosure, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof, has a superior effect of treating and preventing an ischemic injury. Accordingly, a composition containing the peptide may be effectively used for an ischemic injury, particularly for an ischemic-reperfusion injury. | 2016-03-24 |
20160082090 | Use of Polysaccharides for Promotion of Enzymatic Activity - This disclosure provides methods and compositions for the promotion of enzymatic activity of Target Enzymes, including but not limited to oligosaccharide/polysaccharide enzymes, protein enzymes, polynucleotide enzymes. The methods involve use of a non-naturally occurring polysaccharide (including but not limited HES) for promoting the enzymatic activity of an enzyme in liquid milieu, wherein the concentration of the polysaccharide in the composition comprising the Target Enzyme is from about 0.01% to about 55% w/v. | 2016-03-24 |
20160082091 | COMPLEMENT FACTOR B ANALOGS AND THEIR USES - The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway. | 2016-03-24 |
20160082092 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 2016-03-24 |
20160082093 | MUCINOUS GLYCOPROTEIN (MUC-1) VACCINE - The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation. | 2016-03-24 |
20160082094 | VACCINE TO PREVENT MYCOPLASMAL INFECTIONS IN WATERFOWL - An improved vaccine for immunization of waterfowl such as ducks and geese comprises an inactivated strain of a | 2016-03-24 |
20160082095 | VACCINE FOR PCV2 AND MYCOPLASMA - A premixed multivalent vaccine in ready-to-use form comprising PCV2 ORF2 capsid antigen and | 2016-03-24 |
20160082096 | VACCINE AGAINST STREPTOCOCCAL INFECTIONS BASED ON RECOMBINANT PROTEINS - An antigenic composition comprises several antigenic components derived from antigens of | 2016-03-24 |
20160082097 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 2016-03-24 |
20160082098 | OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) | 2016-03-24 |
20160082099 | Attenuated African Swine Fever Virus Strain Induces Protection Against Challenge With Homologous Virulent Parental Virus Georgia 2007 Isolate - African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs that has significant economic consequences for swine breeding. Control of ASF has been hampered by the unavailability of vaccines. Recombinant viruses harboring engineered deletions of specific virulence-associated genes induce solid protection against the challenge with parental viruses. Here we report the construction of a recombinant Δ9GL virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate. In vivo, ASFV-G Δ9GL administered intramuscularly (IM) to swine at relatively high doses (10 | 2016-03-24 |
20160082100 | RECOMBINANT SEROTYPE 5 (Ad5) ADENOVIRAL VECTORS - The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy. | 2016-03-24 |
20160082101 | HORSE ALLERGEN AND METHODS - A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector. | 2016-03-24 |
20160082102 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS - The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-H's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-H's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein. | 2016-03-24 |
20160082103 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDS - Embodiments are directed to compositions and methods for treating viral infections. | 2016-03-24 |
20160082104 | Methods and Compositions for the Treatment of Proliferative and Pathogenic Diseases - The invention features peptide fragments containing domain 4 of the | 2016-03-24 |
20160082105 | Antibody Buffering of a Ligand in Vivo - Compositions and methods are provided in embodiments directed to maintaining a desired concentration range of one or more drugs in a subject, and in particular embodiments to maintaining a desired drug concentration in a body compartment in a subject, based on the surprising discovery that antibodies persist in solution in body compartments such that antibody-antigen equilibrium principles can counteract drug clearance mechanisms. One or more antibodies are selected that have a dissociation constant KD that is similar to the desired drug concentration, wherein KD is independent of the affinity of the drug for a specific drug target (receptor) in the subject. | 2016-03-24 |
20160082106 | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound - A composition, in the form of an aqueous solution, including insulin in hexameric form, at least one substituted anionic compound of non-saccharide structure and at least one polyanionic compound other than the substituted anionic compound. | 2016-03-24 |
20160082107 | COMPOSITIONS CONTAINING QUATERNARY AMMONIUM COMPOUNDS - Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions. | 2016-03-24 |
20160082108 | WIREFRAME NANOSTRUCTURES - The present invention generally relates to nanotechnology and, in particular, to wireframe nanostructures which may be formed from nucleic acids. In various aspects, the invention relates to molecular structures having a plurality of vertices and pathways connecting the vertices, which may be formed from nucleic acids, including bundles or tubes of nucleic acids. Such molecular structures may form shapes such as icosahedrons, octahedrons, tetrahedrons, or other polyhedra, which may define an interior space. The interior space may be used, for example, to contain a molecule for further study, or to contain a molecule for drug delivery purposes. In some cases, the molecular structure may be stabilized using relatively short nucleic acid strands that interact with two or more nucleic acid portions within the structure, thereby substantially immobilizing the portions relative to each other. Other aspects of the invention relate to techniques for forming such molecular structures, techniques for using such molecular structures, techniques of promoting such molecular structures, kits involving such molecular structures, and the like. | 2016-03-24 |
20160082109 | COPOLYMER AND NANOPARTICLES OBTAINED THEREFROM FOR DRUG DELIVERY - The present invention concerns a block copolymer composed of two blocks S1 and S2, wherein S1 consists of m(PEG)n, where n is an integer in the range between 4 and 50 and S2 is a random copolymer consisting of the monomer units R1 and R2 where R1 is the monomer unit corresponding to the monomer γ-valerolactone and R2 is the monomer unit corresponding to the monomer selected from the group consisting of ε-caprolactone, δ-valerolactone, β-butyrolactone, ε-caprolactam, δ-valerolactam. A method for the preparation thereof, the use thereof, nanoparticles and a pharmaceutical composition comprising the same is also provided. | 2016-03-24 |
20160082110 | BIOACTIVE TERPOLYMER COMPOSITIONS AND METHODS OF MAKING AND USING SAME - Described herein are terpolymer compositions, kits comprising the compositions, implant devices comprising the compositions, and methods of making and using same, including point of use methods. | 2016-03-24 |
20160082111 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 2016-03-24 |
20160082112 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER - The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastatis of cancer are additional aspects of the present invention. | 2016-03-24 |
20160082113 | ALTERING A B CELL PATHOLOGY USING SELF-DERIVED ANTIGENS IN CONJUNCTION WITH SPECIFIC-BINDING CYTOREDUCTIVE AGENT - A method of treating B cell malignancies or a method for preparing compositions for treating B cell malignancies wherein administration of a specific binding cytoreductive agent is followed by immunization with an autologous Id protein. The two treatments may be sequential, where the administration of the specific binding cytoreductive agent is completed before the administration of the autologous Id protein, or the administration of the specific binding cytoreductive agent and the immunization with an autologous Id protein may occur in an overlapping time course. | 2016-03-24 |
20160082114 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VI). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 2016-03-24 |
20160082115 | Reverse Thermal Gels and Uses Therefor - Biodegradable triblock copolymer compositions are provided which are useful in tissue engineering and drug delivery. The copolymers are reverse thermal gels in that when heated from a lower temperature to a higher temperature, they gel. These gels are useful in drug delivery when complexed with an active agent. For example the compositions can be used for intraocular injection of active agents, such as anti-angiogenic agents for treatment of a maculopathy or retinitis. | 2016-03-24 |
20160082116 | ENGINEERED MICROGELS - Microparticles containing heparin or a heparin-like polymer and a biocompatible polymer are described. The heparin or the heparin-like polymer and the biocompatible polymer can be indirectly linked together by a coupling agent, which can have a structure represented by Formula I, (A) | 2016-03-24 |
20160082117 | LOW MOLECULAR WEIGHT POLYETHYLENE GLYCOL DRUG CONJUGATES HAVING IMPROVED DRUG BIOLOGICAL ACTIVITY - Provided are polyethylene glycol drug conjugates of general formula (I), (II) or (III) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molecules. The conjugates can interact with receptor dimers or polymers, thereby improving the in vivo distribution of the drug, changing the oil and water distribution coefficient, enhancing the pharmacological activity, reducing the blood-brain barrier permeability of the drug, and improving the bioavailability of the drug. | 2016-03-24 |
20160082118 | GLP-1 RECEPTOR AGONIST PEPTIDE GASTRIN CONJUGATES - The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders. | 2016-03-24 |
20160082119 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE - Described herein are methods and compositions for intracellular delivery of therapeutic molecules. Disclosed herein are selective delivery conjugate comprising a targeting ligand conjugated to a selective delivery molecule (a) an acidic sequence (portion of A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion of B), and (c) a linker between portion of A and portion of B, and (d) at least one cargo moiety. Also, described are selective delivery molecules comprising a second linker comprising an intracellular cleavage site and optionally a self-immolative cleavage site. | 2016-03-24 |
20160082120 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES - Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents. | 2016-03-24 |
20160082121 | BISPECIFIC INTRACELLULAR DELIVERY VEHICLES - A composition for delivering an agent to a cell, comprising a bispecific affinity reagent and a pH-responsive, membrane destabilizing polymer. The bispecific affinity reagent may include a first affinity reagent covalently linked to a second affinity reagent, wherein the first affinity reagent binds to a molecule on the surface of a cell, and the second affinity reagent binds to an intracellular target. | 2016-03-24 |
20160082122 | NON-IMMUNOGENIC AND NUCLEASE RESISTANT NUCLEIC ACID ORIGAMI DEVICES AND COMPOSITIONS THEREOF - Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuation or prevention of internalization of cell-surface receptors or prolongation of shelf-life of active agents. Further provided are methods for treating diabetes and methods for preparing the devices. | 2016-03-24 |
20160082123 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs - The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-biologically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament. | 2016-03-24 |
20160082124 | DRUG DELIVERY SYSTEM AND METHOD - A system for delivering a therapeutic dose of a drug is disclosed. The system includes a delivery medium with therapeutic units attached thereto. The delivery medium is preferably a polymeric hydrogel matrix that has therapeutic units incorporated therein or metal nanoparticles with therapeutic units complexed thereto. The therapeutic units include nucleic acid moieties. The nucleic acid moieties preferably include strands of nucleic acid and drug moieties complexed with the strands of nucleic acid. Where the system includes a polymeric hydrogel matrix, an active drug is controllably released from the polymer hydrogel matrix to provide a therapeutic dose to a biological system or biological tissue. The active drug is controllably released from the hydrogel matrix by altering the environment the hydrogel matrix, or by enzymatic cleavage of the nucleic acid moieties or by a combination thereof. | 2016-03-24 |
20160082125 | Salipro Particles - The invention provides a nanoscale particle comprising a lipid binding polypeptide, lipids and a hydrophobic agent, wherein the hydrophobic agent is different from the lipids, and wherein the lipid binding polypeptide is a saposin-like protein or a derivative or truncated form thereof. The invention further provides a process for preparing a particle comprising a saposin-like protein or a derivative or truncated form thereof and lipids comprising the step of (a) contacting the saposin-like protein or a derivative or truncated form thereof with solubilized lipids in a liquid environment and (b) allowing for the self-assembly of the particle at a pH of from 5.0 to 10.0. In addition, the invention provides a pharmaceutical composition comprising the particle of the invention for delivering a hydrophobic agent to an individual in need thereof and includes the use of the particle of the invention in preventing, treating or lessening the severity of a disease or its use in a diagnostic method, a cosmetic treatment, as hydrophobic agent delivery particle, as a tool for drug development, drug screening, membrane protein research or as vaccination formulation. | 2016-03-24 |
20160082126 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN - A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer. | 2016-03-24 |
20160082127 | PHOTOSENSITIZER PARTICLES FOR MEDICAL IMAGING AND/OR PHOTODYNAMIC THERAPY - Disclosed herein are photosensitizer particle contrast agents suitable for medical imaging and/or photodynamic therapy. The photosensitizer particle contrast agent has a shell and a core encased by the shell. The shell consists essentially of multiple photosensitizer conjugates. Each photosensitizer conjugate consists of a photosensitizer and at least one biodegradable polymer covalently bound to the photosensitizer. According to certain examples, the core has an echogenic contrast-enhancing material loaded therein. In alternative examples, the photosensitizer of at least one of the multiple photosensitizer conjugates has a magnetic contrast-enhancing agent, e.g., a paramagnetic ion, chelated thereto. Also disclosed herein are methods for medical imaging which use imaging compositions containing the photosensitizer particle contrast agents taught in the present disclosure. | 2016-03-24 |
20160082128 | ST-246 LIQUID FORMULATIONS AND METHODS - The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation. | 2016-03-24 |
20160082129 | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector - The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis, comprising administering a nucleic acid that encodes for a tyrosine phosphatase suppressor to a subject. | 2016-03-24 |
20160082130 | Dosage Forms and Methods for Diagnosing Sympathetic Nervous System Dysfunction - Described are methods for detecting and/or diagnosing systemic sympathetic nervous system dysfunction or disease in a subject. One embodiment comprises using a topical apraclonidine eye drop to detect an ocular condition indicative of sympathetic dysfunction or disease in a subject with Guillain-Barré syndrome (GBS). Embodiments can be used to detect and/or diagnose systemic sympathetic nervous system dysfunction or disease early, prior to development of substantial symptoms. Embodiments can also be used to unmask either bilateral ptosis or bilateral Horner's syndrome in GBS patients with the application of the drop to one eye. Also described are dosage forms suitable for use in the methods described herein. The dosage forms comprise an alpha receptor agonist with alpha-1 receptor activity. In one embodiment the dosage form comprises apraclonidine packaged as a single-use eye drop. | 2016-03-24 |
20160082131 | Activatable Membrane-Interacting Peptides and Methods of Use - The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X | 2016-03-24 |
20160082132 | COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MAGNETIC RESONANCE IMAGING (MRI) - Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) or frequency labeled exchange (FLEX) imaging are disclosed. Beta-hydroxycarboxylate and beta-aminocarboxylate derivatives including salicylic acid, salicylates, salicylic acid prodrugs, N-alkyl/aryl/acyl/sulfonyl-anthranilic acid analogs, and any aromatic compound with OH/NH group ortho to the carboxylic acid group are disclosed. Such compounds can be used as general MRI organic contrast agents and produce significantly improved contrast in MR images detectable through CEST or FLEX. | 2016-03-24 |
20160082133 | CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF - The present invention features polypeptide or protein based reporters, wherein the MRI contrast is generated by the protein itself, and methods, MRI systems and MRI imaging kits related thereto. The present invention also features enzyme based reporters, wherein the contrast is generated by the substrate/product of an enzyme, and methods, MRI systems and MRI imaging kits related thereto. | 2016-03-24 |
20160082134 | Nanoparticle Photoacoustic Imaging Agents - The invention described herein relates to colloidal particles useful for photoacoustic imaging. The particles comprise a photoacoustic imaging agent with an absorbance maximum or plateau in the range of wavelengths 700-1100 nm. The imaging agent also displays low optical absorbance at some wavelength in the range 700-1100 nm. This combination of high and low optical absorbance enables background subtraction in photoacoustic imaging applications. The imaging agent is an organic compound having low aqueous solubility so that it is stably encapsulated in the hydrophobic core of the particle. The particle is stabilized by a polymeric surface coating, and the polymeric stabilizing layer on the surface of the particle may contain targeting ligands for targeted diagnostics or therapeutic delivery. The particle core may also contain therapeutic agents or other imaging agents. | 2016-03-24 |
20160082135 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND - It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [ | 2016-03-24 |
20160082136 | METAL COMPLEXES AND FLUORINATION THEREOF - A method of labelling biological molecules with | 2016-03-24 |
20160082137 | Clinical Multimodality-Tools for Pre-And Intraoperative Insulinoma Diagnostics - A chemical compound has the general formula: Ex4-linker-Sar( | 2016-03-24 |
20160082138 | ULTRAVIOLET DISINFECTION UNIT - An ultraviolet (UV) disinfection unit for disinfecting catheter line connections is provided. The unit can be used to disinfect solution set and transfer set catheters used for peritoneal dialysis. The unit can comprise a concavely curved bottom surface. A tubing trough of the unit can allow for ambidextrous positioning. | 2016-03-24 |
20160082139 | DEODORIZING GLOVE HOLDER FOR ATHLETIC GLOVES AND OTHER EQUIPMENT - A deodorizer for insertion into athletic and other equipment, having an outer housing that is infused with an antimicrobial agent and that has ventilation holes, and containing silica within the outer housing. The silica absorbs moisture that allows bacteria to grow and the antimicrobial infused outer housing kills existing bacteria, thereby reducing bacteria and odor. | 2016-03-24 |
20160082140 | FRAGRANT HANGING ORNAMENT - A fragrant hanging ornament has a shell, an absorbing element and a ring. The shell has a chamber and a cover. The cover has a positioning recess, a passage and at least one outlet. The passage is formed in the cover and is in communication with the positioning recess and the at least one outlet. The absorbing element is mounted in the positioning recess and is inserted into the chamber. The ring is mounted on the cover. The absorbing element absorbs a liquid fragrance product in the chamber, and the scent of the liquid fragrance product is diffused through the passage and out of the at least one outlet. A rope can be inserted through the ring, and the combination of the fragrant hanging ornament and the rope is taken as a necklace or a bracelet, so the fragrant hanging ornament is convenient to carry. | 2016-03-24 |
20160082141 | CHITIN AND ALGINATE COMPOSITE FIBERS - Disclosed herein are composite fibers that comprises chitin and alginate. The formation of the chitinous-alginate composite fiber involves the use of ionic liquids and high molecular weight pure chitin obtained directly from chitin biomass. Optional additive such as vitamin E is successfully incorporated in to the composite fiber. The chitinousalginate fiber formed has a continuous and homogenous morphology, even with the addition of additive. Methods of making and using the chitinous-alginate composite fiber as wound dressing is also disclosed. | 2016-03-24 |
20160082142 | Dressing System - The present invention provides a system comprising: (i) a layer containing a nitrite; and (ii) a hydrogel that contains hydrogen ions. The invention also provides the use of a system of the invention for the treatment of a condition associated with tissue ischaemia or a wound and the use of a system of the invention in combination with an anaesthetic for the treatment or prevention of pain. | 2016-03-24 |
20160082143 | Method for Producing an Antibiotic Polymethylmethacrylate Bone Cement Powder, and an Antibiotic Polymethylmethacrylate Bone Cement Powder - The invention relates to a method for producing an antibiotic bone cement, whereby, in a step A), a bone cement base powder with a water content of less than or equal to 1.0% by weight is mixed with trometamol-fosfomycin to form a bone cement powder, and, in a step X), the bone cement powder is dried to a water content of less than or equal to 1.0% by weight. The invention also relates to a bone cement powder that was produced according to said method and contains a bone cement base powder and trometamol-fosfomycin, whereby the bone cement powder has a water content of less than or equal to 1.0% by weight. The bone cement powder is free-flowing and does not clump and can be used for producing bone cements that meet ISO 5833. | 2016-03-24 |
20160082144 | IN-SITU FORMING FOAMS FOR EMBOLIZING OR OCCLUDING A CAVITY - The present invention provides systems and methods for occluding and/or embolizing a cavity within a patient by delivering a prepolymer material into or onto a cavity and forming an expanding foam within the cavity. The inventions methods are applicable to occluding a variety of cavities, including blood vessels, aneurysms, left arterial appendages, vascular malformations and the like. | 2016-03-24 |
20160082145 | SEALANT COMPOSITIONS - The invention provides a combination comprising thrombin, fibrinogen, and lipidated tissue factor, as well as sealant compositions comprising thereof, and their use as a sealant agent as well as in the treatment of hemorrhages. The combination and compositions of the invention shows improved hemostatic properties and, at the same time, the quality of the clot formed is so consistent that the sealant efficiency is improved over those sealant compositions of the prior art. | 2016-03-24 |
20160082146 | COMPOSITION FOR USE IN WOUND HEALING IN BURNS - The preset invention relates to a new method for wound healing, particularly in burns, comprising Epinecidin-1 (Epi-1) or Pardaxin (GE33), optionally in the incorporation into collagen. | 2016-03-24 |
20160082147 | IMPLANTS FOR INDUCING SOFT AND HARD TISSUE INTEGRATION - The present invention provides a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein an antioxidant compound selected from the group of flavonoids or methoxytryptophols, an ester thereof, a pharmaceutically acceptable salt thereof or a combination thereof, is/are coated to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. This implant is useful for replace bone tissue in vertebrate animals, and furthermore restore the normal function of said tissue, mainly due to its ability of induce osseointegration and soft tissue attachment. | 2016-03-24 |
20160082148 | FILM - Disclosed is a film which is able to suppress agglutination by being continuously adhered to an adhesion target portion in a biological body while suppressing a position shift. A film includes an adhesive and an adhesion inhibiting layer. The adhesive layer absorbs and maintains a liquid in a plurality of pores which are opened in one film surface and has a capillary force for adhering the adhesive layer to a first-cell group. The adhesive layer is formed of a biodegradable polymer. The adhesion inhibiting layer configures the other film surface, and inhibits adhesion between a second-cell group which is different from the first-cell group and the adhesive layer. In the adhesive layer, the pore is formed not to be penetrated in a thickness direction of the film, and thus the first-cell group and the second-cell group are separated into the one film surface side and the other film surface side. | 2016-03-24 |
20160082149 | PERIPHERAL NERVE GROWTH CONDUIT - The present invention provides a peripheral nerve growth conduit for peripheral nerve repair, in particular conduits through which peripheral nerves can grow. The conduit includes poly-ε-caprolactone (PCL). Preferably, the inner (luminal) surface of the conduit comprises pits having a depth of 1-4 μm. Suitably, the conduit may also include poly-lactic acid (PLA). The inner surface of the conduit may have been treated with an alkaline composition. The present invention also provides a method for treating a peripheral nerve damage using a peripheral nerve growth conduit including poly-ε-caprolactone (PCL). The present invention also provides a kit for treating a peripheral nerve damage having a peripheral nerve growth conduit including poly-ε-caprolactone (PCL). | 2016-03-24 |
20160082150 | HYALURONIC ACID GELS CROSSLINKED BY SODIUM TRIMETAPHOSPHATE - Injectable dermal fillers including hyaluronic acid crosslinked with trimetaphosphate, and methods of making same are provided. | 2016-03-24 |
20160082151 | ANTIBACTERIAL CORNEA REPAIR MATERIAL AND PREPARATION METHOD THEREOF - Disclosed in the invention is a preparation method of an antibacterial cornea repair material, including the following steps: ( | 2016-03-24 |
20160082152 | Birth Tissue Material and Method of Preparation - A method of treating a soft tissue defect in or on the body of a patient is provided. A placental construct for treatment of a disease or condition is also provided. The placental construct includes a therapeutically effective amount of a birth tissue material. | 2016-03-24 |
20160082153 | Method and System for Treatment of Damaged Biological Tissue - Biomaterial compositions and articles comprising mesothelial tissue and a glycosaminoglycan (GAG), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles can also include additional biologically active agents, such as growth factors. The biomaterial compositions and articles induce modulated healing, including modulation of inflammation and induced neovascularization when administered to damaged biological tissue. | 2016-03-24 |
20160082154 | Method and System for Treatment of Damaged Biological Tissue - Biomaterial compositions and articles comprising mesothelial tissue and a growth factor, for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles induce modulated healing, including modulation of inflammation and induced neovascularization, when administered to damaged biological tissue. | 2016-03-24 |
20160082155 | BONE REPAIR PRODUCT AND METHODS OF USE THEREOF - Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (DBM) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects. | 2016-03-24 |
20160082156 | OSTEOINDUCTIVE SUBSTRATES AND METHODS OF MAKING THE SAME - Systems and methods for preparing osteoinductive synthetic bone grafts are provided in which a porous ceramic granule is loaded with an osteoinductive material, and then placed in contact with a biocompatible matrix material. | 2016-03-24 |
20160082157 | METHODS, SUBSTRATES, AND SYSTEMS USEFUL FOR CELL SEEDING OF MEDICAL GRAFTS - Described are methods, cell growth substrates, and devices that are useful in preparing cell-containing graft materials for administration to patients. Tubular passages can be defined in cell growth substrates to promote distribution of cells into the substrates. Also described are methods and devices for preparing cell-seeded graft compositions, methods and devices for preconditioning cell growth substrates prior to application of cells, and cell seeded grafts having novel substrates, and uses thereof. | 2016-03-24 |
20160082158 | CELLULAR TRANSPLANT SITE - A method of preparing a transplant site for cellular transplantation in a mammal includes the steps of inserting a foreign body comprising a biomaterial into an internal tissue; and removing the foreign body after the tissue surrounding the foreign body has undergone an inflammatory response but before significant fibrous encapsulation has occurred, leaving a neovascularized lumen suitable to receive transplanted cells or islets. | 2016-03-24 |
20160082159 | BALLOON SURFACE COATING - The present invention relates to balloon catheter coated with an active agent and a shellac alkali salt, preferably shellac ammonium salt. Moreover the present invention relates to a method for coating catheter balloons with a pharmacological active agent and an aqueous solution of shellac. | 2016-03-24 |